- Conditions
- CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
- Interventions
- Artesunate vaginal insert, Placebo vaginal insert
- Drug
- Lead sponsor
- Frantz Viral Therapeutics, LLC
- Industry
- Eligibility
- 25 Years to 100 Years · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 34
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
- Interventions
- PVX4 Combination Product, Placebo Control
- Combination Product · Other
- Lead sponsor
- PapiVax Biotech, Inc.
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Cervical Dysplasia
- Interventions
- Nelfinavir
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3
- Interventions
- motexafin lutetium, photodynamic therapy, loop electrosurgical excision procedure, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Stage 0 Cervical Cancer
- Interventions
- Celecoxib, Laboratory Biomarker Analysis, Placebo
- Drug · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 43
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Lewes, Delaware + 32 more
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- ADXS11-001 (Lm-LLO-E7), Placebo Control
- Biological · Drug
- Lead sponsor
- Advaxis, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more
- Conditions
- Atypical Squamous Cell of Undetermined Significance, Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Health Status Unknown, Human Papillomavirus Infection, Low Grade Cervical Squamous Intraepithelial Neoplasia, Stage 0 Cervical Cancer
- Interventions
- Cervical Papanicolaou Test, Cytology Specimen Collection Procedure, Questionnaire Administration, Screening Method
- Other · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 1,335 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Seattle, Washington
- Conditions
- Precancerous Condition
- Interventions
- HspE7
- Biological
- Lead sponsor
- Dana-Farber/Brigham and Women's Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2, High Grade Cervical Intraepithelial Neoplasia
- Interventions
- Imiquimod, Topical Fluorouracil
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
- Interventions
- Artesunate Suppositories
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Towson, Maryland
- Conditions
- Papillomavirus Infections
- Interventions
- VGX-3100
- Biological
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Winston-Salem, North Carolina • Hopwood, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Dysplasia
- Interventions
- 9-valent HPV vaccine, Imiquimod
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Human Papillomavirus, CIN 2, CIN 3
- Interventions
- Not listed
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 13 Years to 22 Years · Female only
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1987 – 2016
- U.S. locations
- 2
- States / cities
- San Francisco, California • San Leandro, California
- Conditions
- Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
- Interventions
- A-007
- Drug
- Lead sponsor
- Tigris Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Costa Mesa, California • Boynton Beach, Florida + 2 more
- Conditions
- Papillomavirus Infections
- Interventions
- 851B
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 22
- States / cities
- Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
- Conditions
- Uterine Cervical Dysplasia
- Interventions
- Amolimogene, Placebo
- Drug · Other
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 13 Years to 25 Years · Female only
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more
- Conditions
- Cervical Cancer, Precancerous Condition
- Interventions
- folic acid, placebo
- Dietary Supplement · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 120 Years · Female only
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- Placebo, RO5217790
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
- Conditions
- Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
- Interventions
- Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery
- Drug · Biological · Other + 2 more
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Oklahoma City, Oklahoma
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- VGX 3100, Placebo, CELLECTRA™-5P
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Colton, California + 24 more
- Conditions
- Cervical Cancer, Precancerous Condition
- Interventions
- Zoledronate, Placebo (Saline)
- Drug · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Interventions
- VGX-3100, Placebo, Electroporation (EP)
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 22
- States / cities
- Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
- Conditions
- Cervical Cancer, Precancerous Condition
- Interventions
- pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
- Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Interventions
- VGX-3100, Matched Placebo, CELLECTRA™-5PSP
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Danbury, Connecticut • Newark, Delaware + 24 more